# Tetrathiomolybdate in Hormone Refractory Prostate Cancer

> **NCT00150995** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Tetrathiomolybdate

## Key facts

- **NCT ID:** NCT00150995
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2003-10
- **Final completion:** 2006-04
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2015-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00150995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00150995, "Tetrathiomolybdate in Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00150995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*